Revenue growth has slowed to 4.1% in 2026Q3 while operating margin compressed to 37.0% from roughly 48% in mid-2025, suggesting rising R&D (to $279.2M) is absorbing operating leverage.
United Therapeutics Corporation (UTHR) annual income statement — 28-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 |
|---|
| Sales/Revenue | 3.19B | 3.18B | 2.88B | 2.33B | 1.94B | 1.69B | 1.48B | 1.45B | 1.63B | 1.73B | 1.6B | 1.47B | 1.29B | 1.12B | 916.08M | 743.18M | 603.83M | 369.85M | 281.5M | 210.94M | 159.63M | 115.92M | 73.59M | 53.34M | 30.12M | 5.73M | 2.05M | 400K | 100K |
| Revenue Growth % | 1.89% | 10.61% | 23.63% | 20.2% | 14.88% | 13.63% | 2.38% | -11% | -5.65% | 7.91% | 9.08% | 13.76% | 15.36% | 21.93% | 23.26% | 23.08% | 63.26% | 31.39% | 33.45% | 32.14% | 37.71% | 57.51% | 37.96% | 77.09% | 425.5% | 179.7% | 412.31% | 300% | - |
| Cost of Goods Sold | 435.4M | 384.4M | 309.7M | 257.5M | 146.7M | 122.5M | 108.1M | 117.6M | 198.7M | 105.7M | 72.7M | 69.04M | 125.88M | 131.13M | 119.3M | 88.9M | 73.47M | 45.32M | 30.07M | 22.26M | 17.03M | 12.31M | 8.25M | 6.78M | 5.46M | 3.14M | 1.71M | 1.4M | 0 |
| COGS % of Revenue | - | 12.08% | 10.76% | 11.06% | 7.58% | 7.27% | 7.29% | 8.12% | 12.21% | 6.13% | 4.55% | 4.71% | 9.77% | 11.74% | 13.02% | 11.96% | 12.17% | 12.25% | 10.68% | 10.55% | 10.67% | 10.62% | 11.21% | 12.72% | 18.11% | 54.73% | 83.24% | 350% | - |
| Gross Profit | 2.75B | 2.8B | 2.57B | 2.07B | 1.79B | 1.56B | 1.38B | 1.33B | 1.43B | 1.62B | 1.53B | 1.4B | 1.16B | 985.86M | 796.78M | 654.28M | 530.37M | 324.53M | 251.43M | 188.68M | 142.6M | 103.6M | 65.34M | 46.56M | 24.66M | 2.59M | 343.47K | -1M | 100K |
| Gross Margin % | 86.34% | 87.92% | 89.24% | 88.94% | 92.42% | 92.73% | 92.71% | 91.88% | 87.79% | 93.87% | 95.45% | 95.29% | 90.23% | 88.26% | 86.98% | 88.04% | 87.83% | 87.75% | 89.32% | 89.45% | 89.33% | 89.38% | 88.79% | 87.28% | 81.89% | 45.27% | 16.76% | -250% | 100% |
| Gross Profit Growth % | - | 8.98% | 24.04% | 15.67% | 14.5% | 13.66% | 3.31% | -6.85% | -11.76% | 6.13% | 9.26% | 20.13% | 17.93% | 23.73% | 21.78% | 23.36% | 63.43% | 29.07% | 33.26% | 32.31% | 37.65% | 58.56% | 40.34% | 88.77% | 850.61% | 655.39% | 134.35% | -1100% | - |
| Operating Expenses | 1.43B | 1.28B | 1.19B | 885.1M | 809.9M | 1.01B | 781.6M | 1.52B | 623.7M | 594.7M | 464.4M | 697.71M | 623.84M | 693.36M | 375.13M | 336.5M | 366.36M | 298.53M | 333.49M | 182.38M | 113.62M | 60.71M | 52.13M | 58.08M | 42.67M | 49.53M | 81.84M | 34.4M | 13.4M |
| OpEx % of Revenue | - | 40.25% | 41.38% | 38.03% | 41.83% | 59.75% | 52.69% | 104.83% | 38.32% | 34.47% | 29.05% | 47.6% | 48.41% | 62.07% | 40.95% | 45.28% | 60.67% | 80.72% | 118.47% | 86.46% | 71.18% | 52.37% | 70.84% | 108.89% | 141.66% | 864.2% | 3993.84% | 8600% | 13400% |
| Selling, General & Admin | 695.5M | 731.1M | 638.6M | 477.1M | 487M | 467M | 423.9M | 336.2M | 265.8M | 330.1M | 316.8M | 452.61M | 381.29M | 394.01M | 201.75M | 156.48M | 199.6M | 176.34M | 94.31M | 99.03M | 54.03M | 24.66M | 21.53M | 22.67M | 15.89M | 16.94M | 11.74M | 5M | 2.4M |
| SG&A % of Revenue | - | 22.97% | 22.19% | 20.5% | 25.15% | 27.71% | 28.58% | 23.21% | 16.33% | 19.13% | 19.81% | 30.88% | 29.59% | 35.27% | 22.02% | 21.06% | 33.06% | 47.68% | 33.5% | 46.94% | 33.85% | 21.27% | 29.26% | 42.49% | 52.75% | 295.6% | 572.7% | 1250% | 2400% |
| Research & Development | 703.2M | 550M | 481M | 408M | 322.9M | 540.1M | 357.7M | 1.18B | 357.9M | 264.6M | 147.6M | 245.1M | 242.55M | 299.35M | 173.39M | 180.01M | 166.76M | 122.19M | 239.18M | 83.35M | 57.57M | 36.05M | 30.6M | 35.42M | 26.78M | 32.59M | 70.19M | 30.7M | 11M |
| R&D % of Revenue | - | 17.28% | 16.72% | 17.53% | 16.68% | 32.04% | 24.12% | 81.63% | 21.99% | 15.34% | 9.23% | 16.72% | 18.82% | 26.8% | 18.93% | 24.22% | 27.62% | 33.04% | 84.97% | 39.51% | 36.06% | 31.1% | 41.58% | 66.4% | 88.9% | 568.6% | 3425.03% | 7675% | 11000% |
| Other Operating Expenses | 1000K | 0 | 71.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.4M | 157K | 3.97M | 635K | 0 | 0 | 0 | 0 | 0 | 0 | 56.05M | 0 | 0 | 0 | 0 | 0 | -79.74K | -1.3M | 0 |
| Operating Income | 1.32B | 1.52B | 1.38B | 1.18B | 979.7M | 555.9M | 593.6M | -187.6M | 805.4M | 814.9M | 1.06B | 699.01M | 538.8M | 292.5M | 421.65M | 317.78M | 164M | 26M | -82.06M | 6.3M | 28.98M | 42.89M | 13.21M | -11.53M | -18M | -46.94M | -81.5M | -35.4M | -13.3M |
| Operating Margin % | 41.47% | 47.67% | 47.86% | 50.91% | 50.6% | 32.98% | 40.02% | -12.95% | 49.48% | 47.23% | 66.41% | 47.69% | 41.82% | 26.19% | 46.03% | 42.76% | 27.16% | 7.03% | -29.15% | 2.99% | 18.16% | 37% | 17.95% | -21.61% | -59.77% | -818.93% | -3977.08% | -8850% | -13300% |
| Operating Income Growth % | - | 10.18% | 16.21% | 20.95% | 76.24% | -6.35% | 416.42% | -123.29% | -1.17% | -23.25% | 51.89% | 29.74% | 84.21% | -30.63% | 32.68% | 93.76% | 530.76% | 131.69% | -1401.86% | -78.25% | -32.43% | 224.73% | 214.6% | 35.98% | 61.65% | 42.41% | -130.23% | -166.17% | - |
| EBITDA | 1.42B | 1.6B | 1.45B | 1.24B | 1.03B | 605.8M | 643.5M | -141.7M | 841.3M | 845.9M | 1.09B | 731.94M | 571.04M | 323.76M | 448.79M | 338.32M | 181.93M | 37.4M | -77.52M | 7.26M | 30.45M | 45.31M | 15.48M | -9.2M | -14.87M | -43.42M | -81.58M | -36.7M | -13.35M |
| EBITDA Margin % | 44.48% | 50.36% | 50.38% | 53.19% | 53.25% | 35.94% | 43.38% | -9.78% | 51.68% | 49.03% | 68.38% | 49.94% | 44.32% | 28.98% | 48.99% | 45.52% | 30.13% | 10.11% | -27.54% | 3.44% | 19.07% | 39.09% | 21.04% | -17.25% | -49.36% | -757.61% | -3980.97% | -9175% | -13346.2% |
| EBITDA Growth % | -10.08% | 10.58% | 17.07% | 20.09% | 70.19% | -5.86% | 554.13% | -116.84% | -0.54% | -22.63% | 49.37% | 28.17% | 76.38% | -27.86% | 32.65% | 85.97% | 386.5% | 148.24% | -1167.77% | -76.15% | -32.8% | 192.59% | 268.3% | 38.12% | 65.76% | 46.77% | -122.29% | -174.98% | - |
| D&A (Non-Cash Add-back) | 96M | 85.6M | 72.5M | 53.2M | 51.3M | 49.9M | 49.9M | 45.9M | 35.9M | 31M | 31.6M | 32.92M | 32.24M | 31.26M | 27.14M | 20.54M | 17.92M | 11.39M | 4.54M | 957K | 1.46M | 2.41M | 2.28M | 2.33M | 3.13M | 3.51M | -79.74K | -1.3M | 0 |
| EBIT | 1.49B | 1.73B | 1.58B | 1.33B | 989M | 686.9M | 596.4M | -120.8M | 802.5M | 1.02B | 1.06B | 1.05B | 542.77M | 292.5M | 457.31M | 320.48M | 174.86M | 31.64M | -72.28M | 18.76M | 28.98M | 47.55M | 15.45M | -11.53M | -18M | -46.94M | -81.5M | -35.36M | -13.35M |
| Net Interest Income | 138.3M | 172.5M | 156.2M | 103.4M | 12.8M | -1.9M | 5.1M | 0 | 14.7M | 1.9M | -400K | -4.7M | -17.6M | -14.23M | -12.7M | -17.92M | -16.77M | -7.73M | -414K | 11.43M | 10.22M | 5.33M | 2.98M | 2.32M | 4.84M | 9.85M | 10.57M | 0 | 0 |
| Interest Income | 150.2M | 192M | 199.1M | 162.7M | 45.2M | 16.7M | 28.6M | 44.2M | 28.6M | 10.9M | 3.5M | 0 | 0 | 3.83M | 3.94M | 3.45M | 2.94M | 5.15M | 11.03M | 13.6M | 10.7M | 5.36M | 2.99M | 2.44M | 4.95M | 10.02M | 10.69M | 0 | 0 |
| Interest Expense | 11.9M | 19.5M | 42.9M | 59.3M | 32.4M | 18.6M | 23.5M | 44.2M | 13.9M | 9M | 3.9M | 4.74M | 17.59M | 18.06M | 16.64M | 21.37M | 19.71M | 12.88M | 16K | 2.17M | 482K | 29K | 4K | 112K | 117K | 172.72K | 120.03K | 0 | 0 |
| Other Income/Expense | 185.9M | 196.7M | 162M | 89.4M | -29.1M | 38M | 45.3M | 22.6M | -46.5M | -45.4M | -1.5M | 345.42M | -13.6M | -13.6M | 19.02M | -18.66M | -16.17M | -7.23M | 9.76M | 10.28M | 10.93M | 4.63M | 2.24M | 1.56M | -5.65M | 9.65M | -4.68M | 63.5K | 546.2K |
| Pretax Income | 1.51B | 1.71B | 1.54B | 1.27B | 950.6M | 593.9M | 638.9M | -165M | 758.9M | 769.5M | 1.06B | 1.04B | 525.18M | 278.9M | 440.67M | 299.12M | 147.84M | 18.77M | -72.3M | 16.58M | 39.91M | 47.52M | 15.45M | -9.97M | -23.65M | -37.29M | -86.18M | -35.3M | -12.8M |
| Pretax Margin % | 47.3% | 53.85% | 53.49% | 54.75% | 49.09% | 35.24% | 43.07% | -11.39% | 46.62% | 44.6% | 66.31% | 71.26% | 40.76% | 24.97% | 48.1% | 40.25% | 24.48% | 5.07% | -25.68% | 7.86% | 25% | 41% | 20.99% | -18.69% | -78.52% | -650.55% | -4205.51% | -8825% | -12800% |
| Income Tax | 277M | 379.2M | 343.9M | 289.5M | 223.3M | 118.1M | 124.1M | -60.5M | 169.7M | 351.6M | 346.5M | 392.8M | 185.11M | 104.34M | 136.23M | 81.87M | 41.92M | -695K | -29.51M | -3.28M | -34.06M | -17.49M | 0 | 0 | 0 | -9.65M | -5.89M | -1.9M | 0 |
| Effective Tax Rate % | 18.37% | 22.12% | 22.35% | 22.72% | 23.49% | 19.89% | 19.42% | 36.67% | 22.36% | 45.69% | 32.68% | 37.61% | 35.25% | 37.41% | 30.91% | 27.37% | 28.36% | -3.7% | 40.82% | -19.76% | -85.34% | -36.81% | 0% | 0% | 0% | 25.88% | 6.84% | 5.38% | 0% |
| Net Income | 1.23B | 1.33B | 1.2B | 984.8M | 727.3M | 475.8M | 514.8M | -104.5M | 589.2M | 417.9M | 713.7M | 651.64M | 340.07M | 174.56M | 304.44M | 217.87M | 105.92M | 19.46M | -42.79M | 19.86M | 73.97M | 65.02M | 15.45M | -9.97M | -23.65M | -37.29M | -75.61M | -33.5M | -12.8M |
| Net Margin % | 38.61% | 41.94% | 41.53% | 42.31% | 37.56% | 28.23% | 34.71% | -7.21% | 36.2% | 24.22% | 44.64% | 44.46% | 26.39% | 15.63% | 33.23% | 29.32% | 17.54% | 5.26% | -15.2% | 9.41% | 46.33% | 56.09% | 20.99% | -18.69% | -78.52% | -650.55% | -3689.55% | -8375% | -12800% |
| Net Income Growth % | -3.22% | 11.68% | 21.35% | 35.4% | 52.86% | -7.58% | 592.63% | -117.74% | 40.99% | -41.45% | 9.52% | 91.62% | 94.82% | -42.66% | 39.74% | 105.7% | 444.22% | 145.48% | -315.46% | -73.15% | 13.76% | 320.84% | 254.97% | 57.85% | 36.57% | 50.68% | -125.7% | -161.72% | - |
| Net Income (Continuing) | 1.23B | 1.33B | 1.2B | 984.8M | 727.3M | 475.8M | 514.8M | -104.5M | 589.2M | 417.9M | 713.7M | 651.64M | 340.07M | 174.56M | 304.44M | 217.24M | 111.21M | 19.46M | -42.79M | 19.86M | 73.97M | 65.02M | 15.45M | -9.97M | -23.65M | -37.29M | -75.61M | -33.5M | -12.8M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 27.17 | 27.86 | 24.64 | 19.81 | 15.00 | 10.06 | 11.54 | -2.39 | 13.39 | 9.31 | 15.25 | 12.72 | 6.28 | 3.28 | 5.71 | 3.67 | 1.78 | 0.35 | -0.93 | 0.44 | 1.53 | 1.29 | 0.33 | -0.24 | -0.57 | -0.92 | -1.97 | -1.26 | -0.77 |
| EPS Growth % | 0.27% | 13.07% | 24.38% | 32.07% | 49.11% | -12.83% | 582.85% | -117.85% | 43.82% | -38.95% | 19.89% | 102.55% | 91.46% | -42.56% | 55.59% | 106.18% | 408.57% | 137.63% | -311.36% | -71.24% | 18.6% | 290.91% | 237.5% | 57.89% | 38.04% | 53.3% | -56.35% | -63.64% | - |
| EPS (Basic) | - | 30.13 | 26.44 | 21.04 | 15.98 | 10.60 | 11.65 | -2.39 | 13.54 | 9.50 | 16.29 | 14.17 | 7.06 | 3.49 | 5.84 | 3.81 | 1.89 | 0.37 | -0.93 | 0.47 | 1.61 | 1.43 | 0.36 | -0.24 | -0.57 | -0.92 | -1.97 | -1.26 | -0.77 |
| Diluted Shares Outstanding | 45.3M | 47.9M | 48.5M | 49.7M | 48.5M | 47.3M | 44.6M | 43.8M | 44M | 44.9M | 46.8M | 51.22M | 54.16M | 53.23M | 53.28M | 59.4M | 59.52M | 56.13M | 45.8M | 44.9M | 48.28M | 50.41M | 46.7M | 42.27M | 41.29M | 40.57M | 38.47M | 26.69M | 16.64M |
| Basic Shares Outstanding | 42.7M | 44.3M | 45.2M | 46.8M | 45.5M | 44.9M | 44.2M | 43.8M | 43.5M | 44M | 43.8M | 46M | 48.18M | 50.08M | 52.09M | 57.16M | 56.14M | 53.31M | 45.8M | 42.45M | 46.02M | 45.65M | 43.45M | 42.27M | 41.29M | 40.57M | 38.47M | 26.69M | 16.64M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying UTHR stock.
For fiscal year 2025, United Therapeutics Corporation (UTHR) reported total revenue of $3.18B. This represents a 3182600.0% increase compared to $0.1M in 1998.
United Therapeutics Corporation (UTHR) is profitable, generating $1.33B in net income for the fiscal year ending 2025 with a net profit margin of 41.9%.
United Therapeutics Corporation (UTHR) reported an operating income of $1.52B, resulting in an operating profit margin of 47.7%. This margin reflects the operational efficiency of the business before interest and taxes.
United Therapeutics Corporation (UTHR) generated $2.80B in gross profit for the year, representing a gross profit margin of 87.9%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Tyvaso generic and Winrevair competition
Metrics are mathematically derived from official filings.
Top-Line Growth Plateauing Near $800M
Based on reported quarterly figures, UTHR's revenue reached $832.5M in 2026Q3, up 4.1% year over year, a marked deceleration from the mid-teens growth rates recorded through 2024 and early 2025.
The reported figures suggest the core treprostinil franchise has matured, with quarterly revenue oscillating in a narrow $780M to $830M band since early 2025. The deceleration may reflect saturation in the nebulized Tyvaso base alongside early generic pressure on Adcirca, though the reported data does not isolate volume from pricing contributions. Investors should monitor whether PH-ILD uptake and Tyvaso DPI conversion can re-accelerate top-line growth or whether the plateau persists.
Gross Margin Holds Near 88 Percent
As reported in the income statement, UTHR's gross margin averaged roughly 87 to 89 percent across most periods, with the Q1 2026 dip to 82.9 percent standing out as the primary deviation from that range.
The consistency of gross margin around 88 percent is consistent with the pricing power typically associated with orphan-drug franchises and low marginal synthesis cost of treprostinil. The Q1 2026 compression appears linked to a sharp rise in COGS to $133.4M, which may reflect channel or royalty timing rather than a structural shift, though the filings alone do not confirm the cause. Sustained margin erosion toward the low 80s would warrant concern about generic pricing pressure.
Operating Margin Compresses From Peak
Based on reported figures, UTHR's operating margin fell from roughly 48 percent in mid-2025 to 37.0 percent in 2026Q3, as operating income declined while R&D expense rose toward $279M.
Operating income has declined from above $380M in early 2025 to $307.8M in the latest quarter, indicating negative operating leverage as revenue flattened while costs rose. R&D spending, which more than doubled sequentially in 2026Q3 relative to the prior quarter, appears to be the dominant driver of this compression. The trend suggests that near-term profitability is sensitive to the pace of pipeline investment, and investors should monitor whether R&D intensity moderates.
EPS Miss Outpaces Operating Decline
According to reported figures, UTHR's 2026Q3 diluted EPS of $5.71 declined 20.3 percent year over year, a sharper drop than the 9.9 percent decline in operating income would imply on its own.
The gap between EPS decline and operating income decline may reflect below-the-line items, tax rate changes, or share count effects, though the provided data does not itemize these. Net income of $258.6M against operating income of $307.8M implies meaningful non-operating drag in the latest quarter. Analysts should reconcile the bridge from operating to net income before drawing conclusions about underlying earnings power.
Pipeline Spend Masks Franchise Risk
The bullish management framing of extraordinary growth appears difficult to reconcile with reported revenue growth of 4.1 percent and a 20.3 percent EPS decline, suggesting the thesis depends heavily on unquantified pipeline contributions.
The strongest bear case is that rising R&D spend and the absence of quantified guidance may be deferring recognition of franchise erosion from Tyvaso generic entry and Winrevair competition. If core PAH revenue is under pressure, pipeline spending could be consuming cash that might otherwise support earnings. Investors may wish to assess whether IPF and organ manufacturing milestones are sufficiently de-risked to justify current R&D intensity, recognizing that these conclusions rely on limited disclosed data.